<DOC>
	<DOCNO>NCT02615639</DOCNO>
	<brief_summary>The anti-virus effect satisfy Chronic Hepatitis B（CHB ) patient anti-Hepatitis B Virus ( HBV ) drug therapy . Dendritic cell ( DC ) critical Hepatitis B Virus ( HBV ) specific immunity process produce HBV promoter specific cytotoxic T cell ( CTLs ) specific T helper cell ( HTLs ) , however defective CHB patient . Therefore , go remove HBV completely , mainly depend body produce enough HBV specific cytotoxic T cell ( CTLs ) specific T helper cell ( HTLs ) . Our research plus Hepatitis B Vaccine Activated-DCs therapy CHB patient anti-HBV drug poor effect , suppose significantly improve anti-HBV efficacy , even clean HBV patient .</brief_summary>
	<brief_title>A Clinical Trial Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs CHB</brief_title>
	<detailed_description>Patients anti-HBV therapy Complying inclusion criterion enrol research , Nucleoside analogues ( NAs , entecavir） treatment 1 year interferon（IFN ) -a-2a ( IFN-a-2a , Pegasys） treatment 24 week . The patient randomly assign experimental group control group ratio 2:1 , one group ( control group ) go receive anti-HBV drug treatment solely ; another group ( experimental group ) enrollment immediately receive Hepatitis B Vaccine activated-DCs ( HPDC-T cell ) 24 week ( every 2 week 24 week , 12 time total ) , time co-use anti-HBV drug treatment , Pegasys , go used 12 week HPDC-T cell treatment complete . The technical route HBV-T cell prepare : First , investigator collect fresh blood CHB , mononuclear cell isolate , induced HBsAg pulse DCs Hepatitis B vaccine ( Shenzhen kangtai , Shenzhen , China ) interleukin-4（IL-4 ) /granulocyte-macrophage colony-stimulating factor ( GM-CSF） ( Perprotech , New Jersey , USA ) ( 7 day ) , co-culture DCs Peripheral Blood Mononuclear Cell ( PBMCs ）7days , obtain HBV specific T cell , return patient finally .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>chronic hepatitis B patient , age 18~65，Chinese entecavir（ETV） telbivudine（LDT） treatment 1 year , HBV DNA &lt; 100 IU/ml（Roche Cobas） ; PEGIFN treatment 24 week , 20 &lt; HBV DNA &lt; 20000 IU/ml（Roche Cobas） . HBsAg 100~5000 IU/ml HBeAg 10~500 COI Superinfection coinfection hepatitis A , C , D , E , cytomegalovirus HIV , EpsteinBarr virus ; liver diseases alcoholic liver disease , druginduced hepatitis , Wilson disease autoimmune hepatitis ; ascites gastrointestinal bleeding peptic ulcer esophageal varix electronic gastroscope examination ; liver cirrhosis ( include compensate decompensated cirrhosis ) liver failure ; severe bacterial fungal infection ; history diabetes cardiac disease hypertension nephrosis ; pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HPDC-T cell</keyword>
	<keyword>CHB</keyword>
	<keyword>immuno therapy</keyword>
</DOC>